{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T09:40:08Z","timestamp":1688895608281},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,28]],"date-time":"2013-12-28T00:00:00Z","timestamp":1388188800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s11934-013-0374-1","type":"journal-article","created":{"date-parts":[[2013,12,27]],"date-time":"2013-12-27T02:15:18Z","timestamp":1388110518000},"source":"Crossref","is-referenced-by-count":1,"title":["Prophylactic effects of Bacille Calmette-Gu\u00e9rin intravesical instillation therapy: Time period-related comparison between Japan and Western countries"],"prefix":"10.1007","volume":"15","author":[{"given":"Takehiko","family":"Okamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Akita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyasu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Tozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Kohri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Arano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,28]]},"reference":[{"key":"374_CR1","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)68208-0","volume":"162","author":"JA Smith Jr","year":"1999","unstructured":"Smith Jr JA, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol. 1999;162:1697\u2013701.","journal-title":"J Urol"},{"key":"374_CR2","unstructured":"Oosterlinck W, Lobel B, Jackse G, Malmstr\u00f6m PU, St\u00f6ckle M, Strenberg C; European Association of Urology. EAU Recommendations 2001. \"Guidelines on bladder cancer\", 2001."},{"key":"374_CR3","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1464-410X.2006.06144.x","volume":"97","author":"HE Schwaibold","year":"2006","unstructured":"Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006;97:1199\u2013201.","journal-title":"BJU Int."},{"key":"374_CR4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1464-410X.2005.05710.x","volume":"96","author":"S Sivalingam","year":"2005","unstructured":"Sivalingam S, Probert JL, Schwaibold H. The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer. BJU Int. 2005;96:759\u201362.","journal-title":"BJU Int."},{"key":"374_CR5","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","volume":"186","author":"M Brausi","year":"2012","unstructured":"\u2022\u2022 Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2012;186:2158\u201367. This paper reports a review of most major current guidelines and emphasized the importance of re-TUR for the management of NMIBC..","journal-title":"J Urol"},{"key":"374_CR6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.5980\/jpnjurol1989.80.1459","volume":"80","author":"M Tachibana","year":"1989","unstructured":"Tachibana M, Jitsukawa S, Iigaya T, Shibayama T, Baba S, Deguchi N, et al. Comparative study on prophylactic intravesical instillation of bacillus Calmette-Guerin (BCG) and adriamycin for superficial bladder cancers. Jpn J Urol. 1989;80:1459\u201365.","journal-title":"Jpn J Urol."},{"key":"374_CR7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.5980\/jpnjurol1989.81.997","volume":"81","author":"T Yamamoto","year":"1990","unstructured":"Yamamoto T, Hagiwara M, Nakazono M, Yamamoto H. Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. Prospective randomized study for prophylactic effect. Jpn J Urol. 1990;81:997\u20131001.","journal-title":"Jpn J Urol"},{"key":"374_CR8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5980\/jpnjurol1989.82.290","volume":"82","author":"N Yabusaki","year":"1991","unstructured":"Yabusaki N, Komatsu H, Tago K, Yamada Y, Ueno A. Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin. Jpn J Urol. 1991;82:290\u20136.","journal-title":"Jpn J Urol."},{"key":"374_CR9","first-page":"79","volume":"16","author":"S Ozono","year":"1992","unstructured":"Ozono S, Tabata S, Kaneko Y, Maruyama Y, Babaya K, Yamada K, et al. Outcomes of intravesical instillation of bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. Ann Soc BCG BRM Imm. 1992;16:79\u201383.","journal-title":"Ann Soc BCG BRM Imm."},{"key":"374_CR10","first-page":"987","volume":"39","author":"T Ao","year":"1993","unstructured":"Ao T, Uchida T, Yokoyama E, Kawakami T, Adachi K, Mashimo S, et al. Prophylactic combination therapy after TUR of superficial bladder cancer. Acta Urol Jpn. 1993;39:987\u201391.","journal-title":"Acta Urol Jpn."},{"key":"374_CR11","first-page":"39","volume":"17","author":"M Kano","year":"1993","unstructured":"Kano M, Kanemura M, Yokoyama M. Risk factor of tumor recurrence following intravesical instillation of bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. Ann Soc BCG BRM Imm. 1993;17:39\u201344.","journal-title":"Ann Soc BCG BRM Imm."},{"key":"374_CR12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.5980\/jpnjurol1989.84.656","volume":"84","author":"M Tachibana","year":"1993","unstructured":"Tachibana M, Nakamura S, Jitsukawa S, Deguchi N, Baba S, Hata M, et al. Long-term results and risk factors of tumor recurrence in patients with superficial bladder cancer who were treated by intravesical bacillus Calmette-Guerin (BCG) instillation. Jpn J Urol. 1993;84:656\u201361.","journal-title":"Jpn J Urol."},{"key":"374_CR13","first-page":"873","volume":"40","author":"A Irie","year":"1994","unstructured":"Irie A, Lee KE, Kadowaki K, Sawamura M. Long-term results and complications of intravesical instillation of bacillus Calmette-Guerin for prophylaxis of bladder cancer recurrence. Acta Urol Jpn. 1994;40:873\u20137.","journal-title":"Acta Urol Jpn."},{"key":"374_CR14","first-page":"95","volume":"18","author":"T Tanaka","year":"1994","unstructured":"Tanaka T, Shinoda M, Maruyama T, Sasaki H, Naga H, Kuwahara Y, et al. The 25 cases of tumor recurrence after intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Ann Soc BCG BRM Imm. 1994;18:95\u2013100.","journal-title":"Ann Soc BCG BRM Imm."},{"key":"374_CR15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/BF02552138","volume":"27","author":"M Takashi","year":"1995","unstructured":"Takashi M, Wakai K, Ohno Y, Murase T, Miyake K. Evaluation of a low-dose intravesical bacillus Calmette-Gu\u00e9rin (Tokyo strain) therapy for superficial bladder cancer. Int Urol and Nephrol. 1995;27:723\u201333.","journal-title":"Int Urol and Nephrol."},{"key":"374_CR16","first-page":"538","volume":"5","author":"T Ao","year":"1996","unstructured":"Ao T, Uchida T, Muramoto M, Ito K, Masui N, Kawakami T, et al. Postoperative intravesical pirarubicin plus bacillus Calmette-Gu\u00e9rin with or without interleukin-2 instillation therapy for superficial bladder cancer. Nishinihon J Urol. 1996;5:538\u201341.","journal-title":"Nishinihon J Urol."},{"key":"374_CR17","first-page":"87","volume":"21","author":"S Ozono","year":"1997","unstructured":"Ozono S, Takashima K, Yoshida K, Hirao Y, Samma S, Okajima E. Intravesical bacillus Calmette-Guerin (BCG) therapy for prophylaxis of the superficial bladder cancer \u2013 Outcomes of randomized study-. Ann Soc BCG BRM Imm. 1997;21:87\u201391.","journal-title":"Ann Soc BCG BRM Imm."},{"key":"374_CR18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000051005","volume":"67","author":"K Tozawa","year":"2001","unstructured":"Tozawa K, Okamura T, Yamada Y, Hayashi Y, Sasaki S, Kohri K. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Gu\u00e9rin is not indicated for superficial bladder cancer. Urol Int. 2001;67:289\u201392.","journal-title":"Urol Int."},{"key":"374_CR19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.0919-8172.2003.00607.x","volume":"10","author":"A Irie","year":"2003","unstructured":"Irie A, Uchida T, Yamashita H, Matsumoto K, Satoh T, Koh H, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Gu\u00e9rin for superficial bladder cancer recurrence. Int J Urol. 2003;10:183\u20139.","journal-title":"Int J Urol."},{"key":"374_CR20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.urology.2005.09.045","volume":"67","author":"S Hinotsu","year":"2006","unstructured":"Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, et al. BCG Tokyo 172 Strain Study Group. Sustained prophylactic effect of intravesical bacille Calmette-Gu\u00e9rin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology. 2006;67:545\u20139.","journal-title":"Urology."},{"key":"374_CR21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1442-2042.2008.02235.x","volume":"16","author":"E Kikuchi","year":"2009","unstructured":"Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, et al. Cancer Registration Committee of the Japanese Urological Association. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999\u20132001 report from the Japanese Urological Association. Int J Urol. 2009;16:279\u201386.","journal-title":"Int J Urol."},{"key":"374_CR22","first-page":"175","volume":"55","author":"N Segawa","year":"2009","unstructured":"Segawa N, Inamoto T, Nomi H, Ibuki N, Azuma H, Katsuoka Y. Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer. Acta Urol Jpn. 2009;55:175\u201380.","journal-title":"Acta Urol Jpn."},{"key":"374_CR23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","volume":"108","author":"S Hinotsu","year":"2011","unstructured":"Hinotsu S, Akaza H, Naito S, Ozono S, Sumiyoshi Y, Noguchi S, et al. Maintenance therapy with bacillus Calmette-Gu\u00e9rin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscleinvasive bladder cancer. BJU Int. 2011;108:187\u201395.","journal-title":"BJU Int."},{"key":"374_CR24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-5347(17)46972-2","volume":"134","author":"DL Lamm","year":"1985","unstructured":"Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol. 1985;134:40\u20137.","journal-title":"J Urol."},{"key":"374_CR25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0090-4295(85)90525-4","volume":"25","author":"HW Herr","year":"1985","unstructured":"Herr HW, Pinsky CM, Whitmore Jr WF, Sogani PG, Oettgen HF, Melamed MR. Experience with intravesical bacillus Calmette-Gu\u00e8rin therapy of superficial bladder tumors. Urology. 1985;25:119\u201323.","journal-title":"Urology."},{"key":"374_CR26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","volume":"5","author":"RA Badalament","year":"1987","unstructured":"Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore Jr WF, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Gu\u00e9rin therapy of superficial bladder cancer. J Clin Oncol. 1987;5:441\u20139.","journal-title":"J Clin Oncol."},{"key":"374_CR27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","volume":"143","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"1990","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Jim\u00e9nez Le\u00f3n J, Mart\u00ednez-Pi\u00f1eiro Jr L, Fiter L, Mosteiro JA, Navarro J, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990;143:502\u20136.","journal-title":"J Urol."},{"key":"374_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-5347(17)39367-9","volume":"144","author":"DL Lamm","year":"1990","unstructured":"Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D, Sarosdy MF. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer. J Urol. 1990;144:65\u20137.","journal-title":"J Urol."},{"key":"374_CR29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/21681805.1991.12068886","volume":"138","author":"KE Jauhiainen","year":"1991","unstructured":"Jauhiainen KE, Alfthan OS. Instillation therapy in superficial urinary bladder cancer. Finnbladder Group. Scand J Urol Nephrol Suppl. 1991;138:179\u201385.","journal-title":"Scand J Urol Nephrol Suppl."},{"key":"374_CR30","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0022-5347(17)38379-9","volume":"145","author":"CA D'Ancona","year":"1991","unstructured":"D'Ancona CA, Netto J\u00fanior NR, Claro JA, Ikari O. Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma. J Urol. 1991;145:498\u2013501.","journal-title":"J Urol."},{"key":"374_CR31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000282516","volume":"51","author":"JA Witjes","year":"1993","unstructured":"Witjes JA, Fransen MP, van der Meijden AP, Doesburg WH, Debruyne FM. Use of maintenance intravesical bacillus Calmette-Gu\u00e9rin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study. Urol Int. 1993;51:67\u201372.","journal-title":"Urol Int."},{"key":"374_CR32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-5347(17)34863-2","volume":"151","author":"DL Lamm","year":"1994","unstructured":"Lamm DL, Riggs DR, Shriver JS, van Gilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994;151:21\u20136.","journal-title":"J Urol"},{"key":"374_CR33","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0022-5347(17)32436-9","volume":"152","author":"MR Kamat","year":"1994","unstructured":"Kamat MR, Kulkarni JN, Tongaonkar HB, Dalal AV. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain. J Urol. 1994;152:1424\u20138.","journal-title":"J Urol."},{"key":"374_CR34","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","volume":"153","author":"PD Vegt","year":"1995","unstructured":"Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, van der Meijden AP. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol. 1995;153:929\u201333.","journal-title":"J Urol."},{"key":"374_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","volume":"1","author":"DL Lamm","year":"1995","unstructured":"Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith Jr JA, et al. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol. 1995;1:119\u201326.","journal-title":"Urol Oncol."},{"key":"374_CR36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","volume":"155","author":"W L\u00fcftenegger","year":"1996","unstructured":"L\u00fcftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol. 1996;155:483\u20137.","journal-title":"J Urol."},{"key":"374_CR37","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","volume":"156","author":"S Krege","year":"1996","unstructured":"Krege S, Giani G, Meyer R, Otto T, R\u00fcbben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. J Urol. 1996;156:962\u20136.","journal-title":"J Urol"},{"key":"374_CR38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0022-5347(01)65183-8","volume":"157","author":"IE Gruenwald","year":"1997","unstructured":"Gruenwald IE, Stein A, Rashcovitsky R, Shifroni G, Lurie A. A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer. J Urol. 1997;157:487\u201391.","journal-title":"J Urol."},{"key":"374_CR39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF02550276","volume":"30","author":"F Yal\u00e7inkaya","year":"1998","unstructured":"Yal\u00e7inkaya F, Kami\u015f L, Ozteke O, G\u00fcnl\u00fcsoy B, Yigitba\u015fi O, Unal S. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. Int Urol Nephrol. 1998;30:41\u20134.","journal-title":"Int Urol Nephrol."},{"key":"374_CR40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","volume":"161","author":"PU Malmstrom","year":"1999","unstructured":"Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norl\u00e9n BJ. 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161:1124\u20137.","journal-title":"J Urol."},{"key":"374_CR41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-5347(05)68555-2","volume":"162","author":"B Ali-El-Dein","year":"1999","unstructured":"Ali-El-Dein B, Nabeeh A, Ismail EH, Ghoneim MA. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. J Urol. 1999;162:339\u201342.","journal-title":"J Urol."},{"key":"374_CR42","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder cancer: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124\u20139.","journal-title":"J Urol."},{"key":"374_CR43","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","volume":"165","author":"J Palou","year":"2001","unstructured":"Palou J, Laguna P, Mill\u00e1n-Rodr\u00edguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodr\u00edguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and\/or high grade bladder tumors. J Urol. 2001;165:1488\u201391.","journal-title":"J Urol."},{"key":"374_CR44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","volume":"89","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"2002","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Flores N, Isorna S, Solsona E, Sebasti\u00e1n JL, Pertusa C, et al. for CUETO (Club Urol\u00f3gico Espa\u00f1ol de Tratamiento Oncol\u00f3gico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89:671\u201380.","journal-title":"BJU Int."},{"key":"374_CR45","first-page":"187","volume":"44","author":"D Librenjak","year":"2003","unstructured":"Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Croat Med J. 2003;44:187\u201392.","journal-title":"Croat Med J."},{"key":"374_CR46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1442-2042.2005.01064.x","volume":"12","author":"CW Cheng","year":"2005","unstructured":"Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, et al. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Int J Urol. 2005;12:449\u201355.","journal-title":"Int J Urol."},{"key":"374_CR47","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","volume":"176","author":"M Colombel","year":"2006","unstructured":"Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176:935\u20139.","journal-title":"J Urol."},{"key":"374_CR48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","volume":"52","author":"MG Friedrich","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52:1123\u20139.","journal-title":"Eur Urol."},{"key":"374_CR49","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"A Ojea","year":"2007","unstructured":"Ojea A, Nogueira JL, Solsona E, Flores N, G\u00f3mez JM, Molina JR, et al. CUETO Group (Club Urol\u00f3gico Espa\u00f1ol De Tratamiento Oncol\u00f3gico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol. 2007;52:1398\u2013406.","journal-title":"Eur Urol."},{"key":"374_CR50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","volume":"57","author":"M Duchek","year":"2010","unstructured":"Duchek M, Johansson R, Jahnson S, Mestad O, Hellstr\u00f6m P, Hellsten S, et al. Members of the Urothelial Cancer Group of the Nordic Association of Urology. Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol. 2010;57:25\u201331.","journal-title":"Eur Urol."},{"key":"374_CR51","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"\u2022\u2022 Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57:766\u201373. This reference emphasized the superior efficacy of maintenance BCG therapy, comparing anti-cancer drug even in intermediate risk group..","journal-title":"Eur Urol"},{"key":"374_CR52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1442-2042.2008.02235.x","volume":"16","author":"E Kikuchi","year":"2009","unstructured":"Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, et al. Mototsugu Oya and Tsuneharu Miki, the Cancer Registration Committee of the Japanese Urological Association Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999\u20132001 report from the Japanese Urological Association. Int J Urol. 2009;16:279\u201386.","journal-title":"Int J Urol."},{"key":"374_CR53","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.urology.2007.11.080","volume":"71","author":"T Yoneyama","year":"2008","unstructured":"Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, et al. Low-dose instillation therapy with bacille Calmette-Gu\u00e9rin Tokyo 172 strain after transurethral resection: historical cohort study. Urology. 2008;71:1161\u20135.","journal-title":"Urology."},{"key":"374_CR54","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","volume":"174","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"2005","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Mart\u00ednez-Pi\u00f1eiro L, Solsona E, Rodr\u00edguez RH, G\u00f3mez JM, Mart\u00edn MG, et al. Club Urol\u00f3gico Espa\u00f1ol de Tratamiento Oncol\u00f3gico (CUETO). Has a 3-fold decreased dose of Bacillus Calmette-Gu\u00e9rin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005;174:1242\u20137.","journal-title":"J Urol."},{"key":"374_CR55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1442-2042.2010.02678.x","volume":"18","author":"RJ Sylvester","year":"2011","unstructured":"Sylvester RJ. Bacillus Calmette-Gu\u00e9rin treatment of non-muscle invasive bladder cancer. Int J Urol. 2011;18:113\u201320.","journal-title":"Int J Urol."},{"key":"374_CR56","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi\u00f1eiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182:2195\u2013203.","journal-title":"J Urol."},{"key":"374_CR57","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","volume":"175","author":"FN Joudi","year":"2006","unstructured":"Joudi FN, Smith BJ, O\u2019Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175:1634\u201340.","journal-title":"J Urol."},{"key":"374_CR58","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00345-010-0514-x","volume":"28","author":"Y Kohjimoto","year":"2010","unstructured":"Kohjimoto Y, Iba A, Shintani Y, Inagaki T, Uekado Y, Hara I. Impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer. World J Urol. 2010;28:425\u201330.","journal-title":"World J Urol."},{"key":"374_CR59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000253403","volume":"4","author":"T Okamura","year":"2010","unstructured":"Okamura T, Akita H, Hashimoto Y, Tozawa K, Hinotsu S, Akaza H, et al. Non Muscle Invasive Bladder Cancer Cases Initially Failing to Respond to Bacillus Calmette-Gu\u00e9rin Intravesical Instillation Therapy. Curr Urol. 2010;4:18\u201324.","journal-title":"Curr Urol."},{"key":"374_CR60","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.urology.2011.04.070","volume":"78","author":"D Margel","year":"2011","unstructured":"\u2022\u2022 Margel D, Alkhateeb SS, Finelli A, Fleshner N. Diminished efficacy of Bacille Calmette-Gu\u00e9rin among elderly patients with nonmuscle invasive bladder cancer. Urology. 2011;78:848\u201355. This study demonstrated the accurate diminished efficacy of BCG among elderly patients rather than younger ones..","journal-title":"Urology"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-013-0374-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-013-0374-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-013-0374-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T09:02:10Z","timestamp":1688893330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-013-0374-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,28]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1007\/s11934-013-0374-1","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,28]]},"article-number":"374"}}